Including patient and public contributors on clinical trial Independent Data Monitoring Committees (IDMCs)
Including patient and public contributors on clinical trial Independent Data Monitoring Committees (IDMCs)
Background and aims: patient and public involvement (PPI) is well established in clinical trials and trial oversight groups in the UK. But public contributors are rarely involved in Independent Data Monitoring Committees (IDMCs), meaning there is little or no evidence for how to include the public in these complex meetings or the impact PPI may have. As a Cancer Research UK core-funded clinical trials unit, the Southampton Clinical Trials Unit (SCTU) coordinates numerous phase II and III cancer drug trials with IDMCs. We aimed to establish a process to include PPI in these committees, but first needed to assess the feasibility of including public contributors and determine what training and resources they need to take part. Here we summarise our process of developing these training and resources to inform others who wish to include public contributors onto trial IDMCs.
Methods and findings: we used design-based and action research methods to develop an initial training programme, working with trial managers and statisticians at the SCTU to ensure key elements of the IDMC process were covered and explained. This was piloted in a SCTU cancer trial, and feedback from the public contributor, trial staff, Chief Investigator and IDMC chair was used to refine the process. The programme was then further evaluated in three more SCTU trials, and feedback was again gathered through participant questionnaires. Our findings show that the training was useful and informative for public contributors, allowing them to contribute meaningfully to IDMC meetings, while constructive feedback allowed us to refine the process further for future roll-out across SCTU trials.
Conclusions: the findings of this project allowed us to develop, review and refine the training materials and resources required for public contributors to meaningfully take part in IDMCs. Furthermore, feedback received from public contributors, trial teams and IDMC chairs was largely positive and suggests that the inclusion of public contributors, when adequate training and resources are provided, is feasible, can enhance the work of these committees and is welcomed by those involved. Limitations to the research and future work have been identified to further assess the impact of including public contributors in IDMCs.
Clinical trials, Independent Data Monitoring Committees(IDMC), PPI training, Patient and public involvement (PPI), Public contributor
Allaway, Elizabeth
a2f5b2aa-5df7-440d-bcca-67df0c2a8003
Soulsby, Irene
35236c31-871e-4f3a-a814-3a7365f32316
Keyworth, Nicole
3040ee74-31cf-4cbd-91ef-3223367f7253
Stanton, Louise
8b827763-d839-4b4b-bbf2-358a84110294
Saunders, Geoff
003d2b6f-fbfd-4247-911c-8b57a83f1fd7
Caddy, Joshua
c9f48059-2d70-45e4-a80a-978bf74fac34
Boxall, Cherish
62deb102-02d5-4613-bd6c-7f2606367b0a
Griffiths, Gareth
7fd300c0-d279-4ff6-842d-aa1f2b9b864d
17 February 2026
Allaway, Elizabeth
a2f5b2aa-5df7-440d-bcca-67df0c2a8003
Soulsby, Irene
35236c31-871e-4f3a-a814-3a7365f32316
Keyworth, Nicole
3040ee74-31cf-4cbd-91ef-3223367f7253
Stanton, Louise
8b827763-d839-4b4b-bbf2-358a84110294
Saunders, Geoff
003d2b6f-fbfd-4247-911c-8b57a83f1fd7
Caddy, Joshua
c9f48059-2d70-45e4-a80a-978bf74fac34
Boxall, Cherish
62deb102-02d5-4613-bd6c-7f2606367b0a
Griffiths, Gareth
7fd300c0-d279-4ff6-842d-aa1f2b9b864d
Allaway, Elizabeth, Soulsby, Irene, Keyworth, Nicole, Stanton, Louise, Saunders, Geoff, Caddy, Joshua, Boxall, Cherish and Griffiths, Gareth
(2026)
Including patient and public contributors on clinical trial Independent Data Monitoring Committees (IDMCs).
Trials, 27 (1), [145].
(doi:10.1186/s13063-026-09559-w).
Abstract
Background and aims: patient and public involvement (PPI) is well established in clinical trials and trial oversight groups in the UK. But public contributors are rarely involved in Independent Data Monitoring Committees (IDMCs), meaning there is little or no evidence for how to include the public in these complex meetings or the impact PPI may have. As a Cancer Research UK core-funded clinical trials unit, the Southampton Clinical Trials Unit (SCTU) coordinates numerous phase II and III cancer drug trials with IDMCs. We aimed to establish a process to include PPI in these committees, but first needed to assess the feasibility of including public contributors and determine what training and resources they need to take part. Here we summarise our process of developing these training and resources to inform others who wish to include public contributors onto trial IDMCs.
Methods and findings: we used design-based and action research methods to develop an initial training programme, working with trial managers and statisticians at the SCTU to ensure key elements of the IDMC process were covered and explained. This was piloted in a SCTU cancer trial, and feedback from the public contributor, trial staff, Chief Investigator and IDMC chair was used to refine the process. The programme was then further evaluated in three more SCTU trials, and feedback was again gathered through participant questionnaires. Our findings show that the training was useful and informative for public contributors, allowing them to contribute meaningfully to IDMC meetings, while constructive feedback allowed us to refine the process further for future roll-out across SCTU trials.
Conclusions: the findings of this project allowed us to develop, review and refine the training materials and resources required for public contributors to meaningfully take part in IDMCs. Furthermore, feedback received from public contributors, trial teams and IDMC chairs was largely positive and suggests that the inclusion of public contributors, when adequate training and resources are provided, is feasible, can enhance the work of these committees and is welcomed by those involved. Limitations to the research and future work have been identified to further assess the impact of including public contributors in IDMCs.
Text
s13063-026-09559-w
- Version of Record
More information
Accepted/In Press date: 6 February 2026
e-pub ahead of print date: 17 February 2026
Published date: 17 February 2026
Keywords:
Clinical trials, Independent Data Monitoring Committees(IDMC), PPI training, Patient and public involvement (PPI), Public contributor
Identifiers
Local EPrints ID: 510166
URI: http://eprints.soton.ac.uk/id/eprint/510166
ISSN: 1745-6215
PURE UUID: 649d47ea-5d78-46f0-bb40-bca9742119c1
Catalogue record
Date deposited: 19 Mar 2026 17:39
Last modified: 20 Mar 2026 02:59
Export record
Altmetrics
Contributors
Author:
Elizabeth Allaway
Author:
Irene Soulsby
Author:
Nicole Keyworth
Author:
Geoff Saunders
Author:
Joshua Caddy
Author:
Cherish Boxall
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics